Molluscum Contagiosum - Pipeline Insight
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Molluscum Contagiosum - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Molluscum Contagiosum pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Molluscum Contagiosum: Overview
Molluscum Contagiosum is a common viral infection of skin that is characterized by pinkish, firm, round, and painless bumps over the skin. The size of the bump can vary from a few mm to 2-5 mm in diameter. The disease is caused by poxvirus Molluscum contagiosum. The lesion becomes red, swollen, and itchy at times and can spread to other areas of the body when scratched (autoinoculation). The disease can spread from person to person through physical contact or contaminated fomites. Though the molluscum contagiosum is common, the persons with weakened immune system, atopic dermatitis, or inhabiting in warm, moist, and crowded places are more prone to the infection. The infection is not age –specific but is most common in children with 1-10 years of age.
“Molluscum Contagiosum - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Molluscum Contagiosum pipeline landscape is provided which includes the disease overview and Molluscum Contagiosum treatment guidelines. The assessment part of the report embraces, in depth Molluscum Contagiosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Molluscum Contagiosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Molluscum Contagiosum R&D. The therapies under development are focused on novel approaches to treat/improve Molluscum Contagiosum.
Molluscum Contagiosum Emerging Drugs Chapters
This segment of the Molluscum Contagiosum report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Molluscum Contagiosum Emerging Drugs
SB 206 (Berdazimer Sodium): Novan Inc
Novans’ new drug candidate, SB 206 is a topically administered drug molecule in development for the treatment of molluscum contagiosum. The phase I and II data demonstrated that SB 206 for the treatment of molluscum contagiosum has beneficial effects on the infection. The drug works on the nitric oxide mechanism of action, where it act as nitric oxide donor to subsequently destroy the virus.
VBP-245 (Povidone Iodine Topical): Veloce Biopharma
Veloce’s drug VBP-245 is currently being evaluated for the treatment of Molluscum Contagiosum and has demonstrated good safety and efficacy profile in phase I trials. VBP-245 is an antiviral drug that inhibits the HN protein responsible for virus attachment to the host cells.
Further product details are provided in the report……..
Molluscum Contagiosum: Therapeutic Assessment
This segment of the report provides insights about the different Molluscum Contagiosum drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Molluscum Contagiosum
There are approx. 10+ key companies which are developing the therapies for Molluscum Contagiosum. The companies which have their Molluscum Contagiosum drug candidates in the most advanced stage, i.e. phase III include, Novan Inc.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Molluscum Contagiosum pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Molluscum Contagiosum: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Molluscum Contagiosum therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Molluscum Contagiosum drugs.
Molluscum Contagiosum Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Molluscum Contagiosum - Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Molluscum Contagiosum pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Molluscum Contagiosum: Overview
Molluscum Contagiosum is a common viral infection of skin that is characterized by pinkish, firm, round, and painless bumps over the skin. The size of the bump can vary from a few mm to 2-5 mm in diameter. The disease is caused by poxvirus Molluscum contagiosum. The lesion becomes red, swollen, and itchy at times and can spread to other areas of the body when scratched (autoinoculation). The disease can spread from person to person through physical contact or contaminated fomites. Though the molluscum contagiosum is common, the persons with weakened immune system, atopic dermatitis, or inhabiting in warm, moist, and crowded places are more prone to the infection. The infection is not age –specific but is most common in children with 1-10 years of age.
“Molluscum Contagiosum - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Molluscum Contagiosum pipeline landscape is provided which includes the disease overview and Molluscum Contagiosum treatment guidelines. The assessment part of the report embraces, in depth Molluscum Contagiosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Molluscum Contagiosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Molluscum Contagiosum R&D. The therapies under development are focused on novel approaches to treat/improve Molluscum Contagiosum.
Molluscum Contagiosum Emerging Drugs Chapters
This segment of the Molluscum Contagiosum report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Molluscum Contagiosum Emerging Drugs
SB 206 (Berdazimer Sodium): Novan Inc
Novans’ new drug candidate, SB 206 is a topically administered drug molecule in development for the treatment of molluscum contagiosum. The phase I and II data demonstrated that SB 206 for the treatment of molluscum contagiosum has beneficial effects on the infection. The drug works on the nitric oxide mechanism of action, where it act as nitric oxide donor to subsequently destroy the virus.
VBP-245 (Povidone Iodine Topical): Veloce Biopharma
Veloce’s drug VBP-245 is currently being evaluated for the treatment of Molluscum Contagiosum and has demonstrated good safety and efficacy profile in phase I trials. VBP-245 is an antiviral drug that inhibits the HN protein responsible for virus attachment to the host cells.
Further product details are provided in the report……..
Molluscum Contagiosum: Therapeutic Assessment
This segment of the report provides insights about the different Molluscum Contagiosum drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Molluscum Contagiosum
There are approx. 10+ key companies which are developing the therapies for Molluscum Contagiosum. The companies which have their Molluscum Contagiosum drug candidates in the most advanced stage, i.e. phase III include, Novan Inc.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Molluscum Contagiosum pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
- Monoclonal Antibody
- Peptides
- Small molecule
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Molluscum Contagiosum: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Molluscum Contagiosum therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Molluscum Contagiosum drugs.
Molluscum Contagiosum Report Insights
- Molluscum Contagiosum Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Molluscum Contagiosum drugs?
- How many Molluscum Contagiosum drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Molluscum Contagiosum?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Molluscum Contagiosum therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Molluscum Contagiosum and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novan
- Veloce Biopharma
- Verrica Pharmaceuticals
- Santalis Healthcare
- SB-206 (Berdazimer Sodium)
- VBP-245 (Povidone Iodine Topical)
- VP-102 (Cantharidin)
- Santalum album cream
Introduction
Executive Summary
Molluscum Contagiosum: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Molluscum Contagiosum – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Molluscum Contagiosum companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Molluscum Contagiosum Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SB 206 (Berdazimer Sodium): Novan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
VBP-245 (Povidone Iodine Topical): Veloce Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative analysis
Molluscum Contagiosum Analyst Views
Molluscum Contagiosum Key Companies
Appendix
Executive Summary
Molluscum Contagiosum: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Molluscum Contagiosum – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Molluscum Contagiosum companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Molluscum Contagiosum Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SB 206 (Berdazimer Sodium): Novan
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
VBP-245 (Povidone Iodine Topical): Veloce Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative analysis
Molluscum Contagiosum Analyst Views
Molluscum Contagiosum Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Molluscum Contagiosum
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Molluscum Contagiosum
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Molluscum Contagiosum
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Molluscum Contagiosum
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
